InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
0
T+90 hit rate
88%
T+90 mean return
+15.2%
Across 8 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by JOHNSON JOHN, Chief Executive Officer. Insider active across 6 companies, notably Strongbridge Biopharma plc. Aggregated, 21 reports have been recorded. Activity tracked since 2 July 2021. The latest transaction was disclosed on 19 December 2024 (Attribution). Regulator: SEC (Form 4). All data is free.
Declarations21 total
14,150 sharesCommon StockSEC:0001410781-26-000006:0
500,000 shares0Common StockSEC:0000950170-24-139240:0
11,904 shares0Common StockSEC:0000805928-24-000121:0
8,333 shares0Common StockSEC:0001104659-24-073599:0
10,653 sharesCommon StockSEC:0000805928-24-000099:0
50,000 shares0Common StockSEC:0001867096-24-000106:0
89,571 sharesCommon StockSEC:0001867096-24-000039:0
215,600 shares@ US$1.99100.0% of flowCommon StockSEC:0001867096-24-000036:0
42,500 shares0Common StockSEC:0001867096-23-000099:0
6,459 shares0Common StockSEC:0000805928-23-000066:0
15,000 shares0Common StockSEC:0001867096-22-000090:0
478,312 sharesCommon StockSEC:0000899243-21-039749:0
478,312 sharesCommon StockSEC:0000899243-21-039749
610,092 sharesOrdinary SharesSEC:0001179110-21-009282:0
610,092 sharesOrdinary SharesSEC:0001179110-21-009282
334,868 shares@ US$2.0681.8% of flowOrdinary SharesSEC:0001179110-21-009224:0
478,312 sharesCommon StockSEC:0000899243-21-039341:0
478,312 sharesCommon StockSEC:0000899243-21-039341
334,868 shares@ US$2.0681.8% of flowOrdinary SharesSEC:0001179110-21-009224
50,867 shares@ US$3.0818.2% of flowOrdinary SharesSEC:0001179110-21-007439
50,867 shares@ US$3.0818.2% of flowOrdinary SharesSEC:0001179110-21-007439:0
21 of 21 declarations
About JOHNSON JOHN
John Johnson is the Chief Executive Officer and Director of Strongbridge Biopharma plc and Xeris Biopharma Holdings, Inc. In these roles, he oversees the operations and strategy of the company. Johnson is recognized for his expertise in the biopharmaceutical sector and his commitment to developing innovative treatments. His leadership is essential in guiding the vision and growth initiatives of Strongbridge and Xeris. He collaborates with management teams to ensure project success and stakeholder satisfaction.
